A Phase II Study of Afatinib (BIBW 2992) in Patients with Adenocarcinoma of the Lung and Activating EGFR/HER1 Mutations (LUX-Lung 2)

被引：0
|
作者：
Yang, Chih-Hsin [1 ]
Shih, Jin Yuan [1 ]
Su, Wu-Chou [2 ]
Hsia, Te-Chun [3 ]
Sequist, Lecia V. [4 ]
Chang, Gee-Chen [5 ]
Calvo, Roser
Cong, Xiuyu Julie
Shahidi, Mehdi
Miller, Vincent A. [6 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[3] China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan
[6] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S376 / S377
页数：2
相关论文
共 50 条
  • [1] A PHASE II STUDY OF BIBW 2992 IN PATIENTS WITH ADENOCARCINOMA OF THE LUNG AND ACTIVATING EGFR/HER1 MUTATIONS (LUX-LUNG 2)
    Yang, C.
    Shih, J.
    Su, W.
    Hsia, T.
    Sequist, L. V.
    Chang, G.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Miller, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [2] A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGER mutations (LUX-Lung 2)
    Yang, C.
    Shih, J.
    Su, W.
    Hsia, T.
    Tsai, C.
    Ou, S. I.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)
    Shih, J.
    Yang, C.
    Su, W.
    Hsia, T.
    Tsai, C.
    Chen, Y.
    Chang, H.
    Terlizzi, E.
    Shahidi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] ACTIVITY OF BIBW 2992, AN IRREVERSIBLE EGFR/HER1 AND HER2 TKI, IN LUNG ADENOCARCINOMA PATIENTS HARBORING LESS COMMON EGFR MUTATIONS
    Shih, J.
    Yu, C.
    Su, W.
    Hsia, T.
    Graziano, S. L.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Yang, C.
    Miller, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 138 - 138
  • [5] LUX-LUNG 4: A PHASE II TRIAL OF AFATINIB (BIBW 2992) IN ADVANCED NSCLC PATIENTS PREVIOUSLY TREATED WITH ERLOTINIB OR GEFITINIB
    Atagi, Shinji
    Katakami, Nobuyuki
    Hida, Toyoaki
    Goto, Koichi
    Horai, Takeshi
    Inoue, Akira
    Sarashina, Akiko
    Seki, Yoko
    Lorence, Robert
    Shahidi, Mehdi
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S360 - S361
  • [6] A Phase II Trial of Afatinib (BIBW 2992) in Patients With Tumours Prospectively Screened for EGFR And/or HER2 Gene Amplification or EGFR Activating Mutations
    Kwak, E. L.
    Shapiro, G. I.
    Cohen, S. M.
    Becerra, C. R.
    Lenz, H. J.
    Gooden, S.
    Robohn, M.
    Le-Maulf, F.
    Chand, V. K.
    Iafrate, A. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S174 - S174
  • [7] BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations
    Yang Chih-Hsin
    Shih Jin-Yuan
    Su Wu-Chou
    Hsia Te-Chun
    Ho Ching-Liang
    Dudek, Arkadiusz Z.
    Terlizzi, Elizabeth
    Zhao Yihua M
    Shahidi, Mehdi
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S294 - S295
  • [8] Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
    De Greve, J.
    Teugels, E.
    Geers, C.
    Decoster, L.
    Galdermans, D.
    De Mey, J.
    Everaert, H.
    Umelo, I.
    In't Veld, P.
    Schallier, D.
    LUNG CANCER, 2012, 76 (01) : 123 - 127
  • [9] CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCINOMA OF THE LUNG WITH MUTATIONS IN THE KINASE DOMAIN OF HER2NEU
    De Greve, J.
    Decoster, L.
    De Mey, J.
    In 't Veld, P.
    Geers, C.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Teugels, E.
    Schallier, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S91
  • [10] Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    Su, Wu-Chou
    Hsia, Te-Chun
    Tsai, Chun-Ming
    Ou, Sai-Hong Ignatius
    Yu, Chung-Jen
    Chang, Gee-Chen
    Ho, Ching-Liang
    Sequist, Lecia V.
    Dudek, Arkadiusz Z.
    Shahidi, Mehdi
    Cong, Xiuyu Julie
    Lorence, Robert M.
    Yang, Pan-Chyr
    Miller, Vincent A.
    LANCET ONCOLOGY, 2012, 13 (05): : 539 - 548
12345